MiCo BioMed Co., Ltd. (KOSDAQ: 214610)

Market Cap	70.52B
Revenue (ttm)	7.23B
Net Income (ttm)	-28.95B
Shares Out	43.56M
EPS (ttm)	-815.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	600,758
Open	1,679.00
Previous Close	1,685.00
Day's Range	1,632.00 - 1,707.00
52-Week Range	1,132.00 - 4,840.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About MiCo BioMed

MiCo BioMed Co., Ltd. provides on-site diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real-time PCR system; PCR and sample prep kits; Veri-Q PCR 316 PB products; and LabChip, sample tube, and pre-filtering column products. It also provides biological chemi...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2009
• Employees: 75
• Stock Exchange: KOSDAQ
• Ticker Symbol: 214610

Financial Performance

In 2023, MiCo BioMed's revenue was 5.37 billion, a decrease of -66.69% compared to the previous year's 16.11 billion. Losses were -25.77 billion, -33.73% less than in 2022.